Use of erythropoietin in heart failure management

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 2145-2149

  Caiola, Krista ^a   Cheng, Judy W M ^b,c  

^a MOUNT SINAI HOSPITAL   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Anemia; Erythropoietin; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; FUROSEMIDE; HEMOGLOBIN; IRON;

ANEMIA; BLOOD CLOTTING DISORDER; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DYSERYTHROPOIESIS; FOLIC ACID DEFICIENCY; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MEDLINE; MORTALITY; NONHUMAN; PEER REVIEW; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HEMATINICS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 12844272142     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E143     Document Type: Review

References (25)

1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
2. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borentstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
3. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36.
4. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223-5.
5. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med 2003;114:112-9.
6. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62.
7. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003;41:1933-9.
8. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003;92:625-8.
9. Szanchniewicz J, Petruk-Kowalczyk J, Manjda J, Kaczmarek A, Reczuch K, Kalra PR, et al. Anemia is an independent predictor of poor outcomes in patients with chronic heart failure. Int J Cardiol 2003;90:303-8.
10. Silverberg DS, Wexler D, Blum M, Schwartz D, Wollman Y, Iaina A. Erythropoietin should be a part of congestive heart failure management. Kidney Int 2003;64(suppl 87):S40-7.
11. Vaziri ND. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 2001;38:1-8.
12. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74:468-73.
13. Pham I, Andrivet P, Sediame S, Defouilloy C, Moutereau S, Wirquin V, et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal hemodynamics. Eur J Clin Invest 2001;31:103-9.
14. Iverson PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integ Comp Physiol 2002;282:R166-72.
15. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, Vooletich MT, Farmer JA, Torre-Amione G. Tumor necrosis factor, a mediator of disease progression in the failing heart. Chest 1999;115:1170-4.
16. MacDougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999;14:1836-41.
17. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230-6.
18. Ng T, Marx G, Littlewood T, MacDougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003;79:367-76.
19. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improved cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44.
20. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
21. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. The effect of correction of anemia in diabetics and non-diabetics with severe resistant heart failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
22. Silverberg DS, Wexler D, Blum M, Schwartz M, Keren G, Sheps D. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Israel Med Assoc J 2003;5:337-9.
23. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne A. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9.
24. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003;100:4802-6.
25. Mitka M. Researchers probe anemia - heart failure link. JAMA 2003;290:1835-8.